Serum Lipids in Association With Type 2 Diabetes Risk and Prevalence in a Chinese Population

Context We previously reported an association between lysophosphatidylinositol (LPI) (16:1) and risk for type 2 diabetes in a Chinese population using an untargeted analysis. Objective To examine the overall associations of LPIs and their related metabolites, such as nonesterified fatty acids (NEFAs) and acylcarnitines, with incident and prevalent type 2 diabetes using a targeted approach. Design and Setting A case-control study was nested within the Singapore Chinese Health Study. Cases and controls were individually matched by age, sex, and date of blood collection. We used both liquid and gas chromatography tandem mass spectrometry to measure serum metabolite levels at baseline, including 8 LPIs, 19 NEFAs, and 34 acylcarnitines. Conditional logistic regression models were used to estimate the associations between metabolites and diabetes risk. Participants Participants included 160 incident and 144 prevalent cases with type 2 diabetes and 304 controls. Main Outcome Measure Incident and prevalent type 2 diabetes. Results On the basis of a false discovery rate <0.1, we identified 37 metabolites associated with prevalent type 2 diabetes, including 7 LPIs, 18 NEFAs, and 12 acylcarnitines, and 11 metabolites associated with incident type 2 diabetes, including 2 LPIs and 9 NEFAs. Two metabolites, LPI (16:1) and dihomo-γ-linolenic acid, showed independent associations with incident type 2 diabetes and significantly enhanced the risk prediction. Conclusions We found several LPIs and NEFAs that were associated with risk for type 2 diabetes and may improve our understanding of the pathogenesis. The findings suggest that lipid profiles could aid in diabetes risk assessment in Chinese populations.

[1]  F. Stephens,et al.  New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle , 2007, The Journal of physiology.

[2]  A. Peters,et al.  Identification of Serum Metabolites Associated With Risk of Type 2 Diabetes Using a Targeted Metabolomic Approach , 2013, Diabetes.

[3]  C. Ong,et al.  Targeted analysis of omega-6-derived oxylipins and parent polyunsaturated fatty acids in serum of hepatitis B virus-related hepatocellular carcinoma patients , 2016, Metabolomics.

[4]  D. van der A,et al.  Association of Plasma Phospholipid n-3 and n-6 Polyunsaturated Fatty Acids with Type 2 Diabetes: The EPIC-InterAct Case-Cohort Study , 2016, PLoS medicine.

[5]  S. Romero-Zerbo,et al.  A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. , 2011, The Journal of endocrinology.

[6]  M. Falasca,et al.  Lysophosphatidylinositol: a novel link between ABC transporters and G-protein-coupled receptors. , 2014, Biochemical Society transactions.

[7]  Choon Nam Ong,et al.  Metabolic signature shift in type 2 diabetes mellitus revealed by mass spectrometry-based metabolomics. , 2013, The Journal of clinical endocrinology and metabolism.

[8]  Christian Gieger,et al.  Biomarkers for Type 2 Diabetes and Impaired Fasting Glucose Using a Nontargeted Metabolomics Approach , 2013, Diabetes.

[9]  L. Irwig,et al.  Assessing new biomarkers and predictive models for use in clinical practice: a clinician's guide. , 2008, Archives of internal medicine.

[10]  R. P. Ross,et al.  Health Implications of High Dietary Omega-6 Polyunsaturated Fatty Acids , 2012, Journal of nutrition and metabolism.

[11]  J. Moreno-Navarrete,et al.  The l-α-Lysophosphatidylinositol/GPR55 System and Its Potential Role in Human Obesity , 2012, Diabetes.

[12]  G. Rossi,et al.  Diagnosis and Classification of Diabetes Mellitus The information that follows is based largely on the reports of the Expert Committee on the Diagnosis and Classification of Diabetes (Diabetes Care 20:1183–1197, 1997, and Diabetes Care 26:3160–3167, 2003). , 2008, Diabetes Care.

[13]  Jian-Min Yuan,et al.  Metabolic signatures and risk of type 2 diabetes in a Chinese population: an untargeted metabolomics study using both LC-MS and GC-MS , 2016, Diabetologia.

[14]  Thomas J. Wang,et al.  Metabolite Profiles of Diabetes Incidence and Intervention Response in the Diabetes Prevention Program , 2016, Diabetes.

[15]  Peter M. Jones,et al.  GPR55‐dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans , 2016, Diabetes, obesity & metabolism.

[16]  A. Yamashita,et al.  Identification of GPR55 as a lysophosphatidylinositol receptor. , 2007, Biochemical and biophysical research communications.

[17]  S. Yi,et al.  High levels of stearic acid, palmitoleic acid, and dihomo-γ-linolenic acid and low levels of linoleic acid in serum cholesterol ester are associated with high insulin resistance. , 2012, Nutrition research.

[18]  Yuanqing Fu,et al.  Marine N-3 Polyunsaturated Fatty Acids Are Inversely Associated with Risk of Type 2 Diabetes in Asians: A Systematic Review and Meta-Analysis , 2012, PloS one.

[19]  L. Liang,et al.  Early Prediction of Developing Type 2 Diabetes by Plasma Acylcarnitines: A Population-Based Study , 2016, Diabetes Care.

[20]  R. V. van Dam,et al.  Dietary predictors and plasma concentrations of perfluorinated alkyl acids in a Singapore population. , 2017, Chemosphere.

[21]  E. Eschwège,et al.  The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study , 1997, Diabetologia.

[22]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[23]  Ying Li,et al.  Fasting serum lipid and dehydroepiandrosterone sulfate as important metabolites for detecting isolated postchallenge diabetes: serum metabolomics via ultra-high-performance LC-MS. , 2013, Clinical chemistry.

[24]  Yi-Zeng Liang,et al.  Plasma fatty acid metabolic profiling and biomarkers of type 2 diabetes mellitus based on GC/MS and PLS‐LDA , 2006, FEBS letters.

[25]  R. Piñeiro,et al.  Lysophosphatidylinositol signalling: new wine from an old bottle. , 2012, Biochimica et biophysica acta.

[26]  V. Mootha,et al.  Metabolite profiles and the risk of developing diabetes , 2011, Nature Network Boston.

[27]  R. Bergenstal,et al.  Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. , 2009, European journal of internal medicine.

[28]  Olga Ilkayeva,et al.  Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. , 2008, Cell metabolism.

[29]  A. Olokoba,et al.  Type 2 diabetes mellitus: a review of current trends. , 2012, Oman medical journal.

[30]  K. Petersen,et al.  Hepatic Acetyl CoA Links Adipose Tissue Inflammation to Hepatic Insulin Resistance and Type 2 Diabetes , 2015, Cell.